View Exam | PowerPak

1. Which protein kinases are especially important in angiogenesis?

A. VEGFR-1, -2, and -3 B. KIT, REF, RAF-1 C. BRAF, BRAFV600E D. PDGFR, FGFR

2. Which of the following statements regarding the use of cabozantinib in patients with renal cell carcinoma (RCC) is TRUE?

A. Tablets and capsules may be used interchangeably. B. Cabozantinib is approved for patients who received prior antiangiogenesis therapy. C. Cabozantinib is approved for first-line treatment of patients with clear-cell histology. D. Cabozantinib is approved in combination with everolimus to treat patients with unresectable RCC.

3. RT is a 58-year-old man with unresectable gastrointestinal stromal tumors. He was previously treated with imatinib and sunitinib but continues to have progressive disease. Which of the following would be the MOST appropriate option for RT at this time?

A. Cabozantinib B. Lenvatinib C. Regorafenib D. Sorafenib

4. Which of the following agents would be the MOST appropriate option for a patient with metastatic differentiated thyroid cancer that is refractory to treatment with radioactive iodine?

A. Alectinib B. Osimertinib C. Sorafenib D. Regorafenib

5. Dermatologic adverse events of tyrosine kinase inhibitors are MOST closely associated with _________ inhibition.

A. VEGF B. EGFR C. MET D. BRAF

6. Regorafenib should be discontinued in patients with:

A. Fatigue B. Any evidence of cardiac ischemia/infarction C. Palmar-plantar erythrodysesthesia D. Gastrointestinal perforation or fistula

7. Nearly all of the oral tyrosine kinase inhibitors used in cancer therapy are metabolized by:

A. CYP2D6 B. CYP3A4 C. CYP1A2 D. CYP2A6

8. KD has been taking oral lenvatinib 24 mg once daily for renal cell carcinoma when she develops oral thrush and is given a prescription for itraconazole, a CYP3A4 inhibitor. Which of the following would be the MOST appropriate treatment adjustment for KD?

A. Discontinue lenvatinib during itraconazole treatment B. Administer itraconazole at one-half of the normal dose C. Administer lenvatinib at one-half the normal dose D. No lenvatinib dose adjustment is necessary

9. Patients who are taking sorafenib should avoid:

A. Strong CYP3A4 inducers B. Strong CYP2D6 inhibitors C. Ketoconazole D. Taking sorafenib on an empty stomach

10. Which of the following is the LEAST appropriate recommendation for the prevention/treatment of cutaneous adverse events for a patient on tyrosine kinase inhibitor therapy?

A. Sunscreen B. Moisturizers C. An alcohol-based cleanser D. Topical hydrocortisone 1%

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which protein kinases are especially important in angiogenesis?

2. Which of the following statements regarding the use of cabozantinib in patients with renal cell carcinoma (RCC) is TRUE?

3. RT is a 58-year-old man with unresectable gastrointestinal stromal tumors. He was previously treated with imatinib and sunitinib but continues to have progressive disease. Which of the following would be the MOST appropriate option for RT at this time?

4. Which of the following agents would be the MOST appropriate option for a patient with metastatic differentiated thyroid cancer that is refractory to treatment with radioactive iodine?

5. Dermatologic adverse events of tyrosine kinase inhibitors are MOST closely associated with _________ inhibition.

6. Regorafenib should be discontinued in patients with:

7. Nearly all of the oral tyrosine kinase inhibitors used in cancer therapy are metabolized by:

8. KD has been taking oral lenvatinib 24 mg once daily for renal cell carcinoma when she develops oral thrush and is given a prescription for itraconazole, a CYP3A4 inhibitor. Which of the following would be the MOST appropriate treatment adjustment for KD?

9. Patients who are taking sorafenib should avoid:

10. Which of the following is the LEAST appropriate recommendation for the prevention/treatment of cutaneous adverse events for a patient on tyrosine kinase inhibitor therapy?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which protein kinases are especially important in angiogenesis?

2. Which of the following statements regarding the use of cabozantinib in patients with renal cell carcinoma (RCC) is TRUE?

3. RT is a 58-year-old man with unresectable gastrointestinal stromal tumors. He was previously treated with imatinib and sunitinib but continues to have progressive disease. Which of the following would be the MOST appropriate option for RT at this time?

4. Which of the following agents would be the MOST appropriate option for a patient with metastatic differentiated thyroid cancer that is refractory to treatment with radioactive iodine?

5. Dermatologic adverse events of tyrosine kinase inhibitors are MOST closely associated with _________ inhibition.

6. Regorafenib should be discontinued in patients with:

7. Nearly all of the oral tyrosine kinase inhibitors used in cancer therapy are metabolized by:

8. KD has been taking oral lenvatinib 24 mg once daily for renal cell carcinoma when she develops oral thrush and is given a prescription for itraconazole, a CYP3A4 inhibitor. Which of the following would be the MOST appropriate treatment adjustment for KD?

9. Patients who are taking sorafenib should avoid:

10. Which of the following is the LEAST appropriate recommendation for the prevention/treatment of cutaneous adverse events for a patient on tyrosine kinase inhibitor therapy?

« Return to Activity

Customers who Purchased
this Activity also Purchased